



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CASPER *et al.*

Appl. No.: 10/806,613

Filed: March 22, 2004

For: **Low Dose Estrogen Interrupted  
Hormone Replacement Therapy**

Confirmation No.: 2635

Art Unit: 1617

Examiner: Badio, Barbara P.

Atty. Docket: 2710.0990003/JUK/MEK

**Amendment and Reply Under 37 C.F.R. § 1.111**

***Mail Stop Petition***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated January 31, 2005, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (C) Starting on a separate sheet, the Remarks.

As this reply is being filed after the deadline for replying to the Office Action, this Amendment is accompanied by a Petition to Revive Under 37 C.F.R. § 1.137(b).

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.